Paige Launches AI Software to Enable Accurate and Efficient Detection of Breast Cancer Metastases in Lymph Nodes
Paige, the global leader in AI-based diagnostic software in pathology, today launched its latest product, Paige Breast Lymph Node, an AI medical device software that helps pathologists detect if breast cancer has metastasized to lymph nodes, concurrent with pathologists’ own interpretive review*. The product was unveiled at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting taking place March 19-24, 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006217/en/
Paige Breast Lymph Node is designed to increase the accuracy and efficiency in the detection of breast cancer metastases that are most at-risk for being missed. (Photo: Paige)
Determining whether cancer in the breast has spread to the lymphatic system is critical to a patient’s diagnosis and planned treatment. Due to the size of the tissue area and size of the small micro-metastases, a pathologist’s accurate assessment of a lymph node slide can be tedious and time-consuming.
Designed to increase the accuracy and efficiency in the detection of breast cancer metastases that are most at-risk for being missed, Paige Breast Lymph Node leverages AI to empower pathologists to identify tumor metastases of any size, including small micrometastases, more efficiently and reliably. It is designed to enhance diagnostic accuracy for the most subtle metastatic foci and has over 98% slide level sensitivity to detect metastases of any size. A positive indication of metastatic breast cancer will be displayed at the individual lymph node level with Paige’s proprietary TissueMap, which highlights all regions on a slide that are suspicious for cancer. In addition, both slides and cases with suspected positive lymph nodes are highlighted, facilitating their prioritization and efficient review by the pathologist.
“Accurate detection of breast cancer metastases is paramount for physicians and their patients, but it can be a laborious, manual task for pathologists,” said David Klimstra, M.D., Founder and Chief Medical Officer at Paige. “Paige Breast Lymph Node offers pathologists a quicker and more efficient way to analyze large quantities of lymph node tissue, as well as peace of mind for them and their patients.”
Paige Breast Lymph Node will be available immediately as part of the Paige Breast Suite. This software uses the same underlying AI technology as Paige Prostate, which can work with a broad range of data, staining techniques, and scanning artifacts, resulting in a generalizable AI that can be quickly deployed in a variety of laboratory and hospital settings.
“Paige Breast Lymph Node bolsters the value of the Paige Breast Suite to clinical pathologists,” said Andy Moye, Ph.D., Chief Executive Officer at Paige. “This product launch is an important step in our overall commercialization strategy as we bring the power of our AI platform to new disease areas. Alongside our FDA-approved Paige Prostate, the generalizability of the AI further validates the broader use of Paige’s software in assisting pathologist to diagnose cancer.”
Paige will host a webinar on March 30 to demonstrate how Paige Breast Lymph Node can be used in clinical practice. For more information about Paige Breast Lymph Node, visit http://info.paige.ai/breast or contact info@paige.ai.
*Paige Breast Lymph Node is available for research use only in United States and in other regions where research use is permitted. Research use only products should not be used in diagnostic procedures.
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., David Klimstra, M.D., and colleagues from Memorial Sloan Kettering Cancer Center (MSK). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA approval for an AI-based digital pathology product.
For additional information, please visit: https://www.paige.ai, Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322006217/en/
Contact information
Jon Yu
ICR Westwicke
Tel: 475.395.5375
Jon.Yu@westwicke.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv811.12.2025 15:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that the International Society for the Advancement of Spine Surgery (ISASS) has issued recommendations and coverage criteria for the use of restorative neurostimulation for the treatment of chronic mechanical low back pain associated with multifidus muscle dysfunction. ReActiv8® restorative neurostimulation is the only therapy approved in the United States, Europe and Australia for this indication. The Statement, which affirms ISASS’ support for coverage by payers of implantable restorative neurostimulation in appropriately selected patients, was published in the December issue of the International Journal of Spine Surgery and can be accessed here: https://www.ijssurgery.com/content/early/2025/12/10/8833. The Statement reflects the growing body of clinical evidence supporting the use of ReActiv8, as well as recent developments in diagnostic coding and reimbursement pathways since ISASS’ 2023 Statement on Restorative Neurostimulation for Chr
SLB Enters Collaboration Agreement to Accelerate New Digital Solutions11.12.2025 15:28:00 EET | Press release
Global energy technology company SLB (NYSE: SLB) signed a strategic collaboration agreement with Shell to develop digital and AI solutions that drive measurable performance and efficiency gains across upstream operations for the company and the wider industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211832051/en/ The collaboration has the ambition to develop agentic AI-powered solutions that will accelerate and amplify the capabilities of technical experts and decision makers. The aim is to develop and deploy an open data and AI infrastructure that unifies data and workflows across subsurface, well construction and production in a secure digital environment, using SLB’s Lumi™ data and AI platform. The collaboration has the ambition to develop agentic AI-powered solutions that will accelerate and amplify the capabilities of technical experts and decision makers. The aim is to develop and deploy an open data and AI i
Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas11.12.2025 15:00:00 EET | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that Tahoe Therapeutics has selected Parse’s GigaLab to generate data for its upcoming 300M cell project. Tahoe will use its proprietary Mosaic technology to generate samples consisting of 300M cells from large arrays of disease models, genetically or chemically perturbed. Under this agreement, Parse will apply its Evercode™ chemistry and high-throughput automation to these samples to deliver the largest perturbation-focused single cell dataset ever produced. Parse’s GigaLab, designed specifically for million- to hundred-million-cell projects, has rapidly become an industry benchmark for large-scale, reproducible single cell data generation. The facility integrates high-capacity liquid handling, standardized workflows, and end-to-end QC to enable dataset sizes previously unattainable for most research organizations. The Tahoe project represents one of the largest sequencin
Xsight Labs X2 Switch to Enable Next-Generation Starlink Satellites and Deliver Gigabit Connectivity11.12.2025 15:00:00 EET | Press release
Xsight Labs, an innovator in high-performance connectivity silicon, today announced that Starlink, the world’s most advanced satellite constellation in low-Earth orbit, delivering broadband, will leverage the Xsight X2 Programmable Ethernet switch to serve as the high-speed networking core for its next-generation Starlink V3 satellites. Each V3 Starlink satellite is designed to deliver more than 1 terabit per second (Tbps) of fronthaul throughput, more than 10× the capacity delivered by Starlink V2 Mini satellites, and about 160 gigabits per second (Gbps) of uplink capacity. Starlink’s global broadband service depends on processing and routing large volumes of real-time data, including inter-satellite optical link traffic, orbital mesh routing decisions, adaptive beam steering, and the high-throughput downlink required to serve its customers. The X2 delivers 12.8 Tbps of switching capacity using state-of-the-art 100G SerDes and TSMC’s N5 process, providing a power-efficient, ultra-low-
Payments Leaders Unprepared for 2026 Disruption, Warns ACI Worldwide11.12.2025 14:36:00 EET | Press release
Most global payments leaders lack a clear roadmap to navigate the seismic changes coming in 2026 , according to the latest Top Ten Payments Predictions from ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology. With AI-driven intelligence, next-gen authentication, new regulatory frameworks, and soaring demand for instant, embedded, and secure payments, the industry is entering an era of structural disruption. However, ACI’s recent report Payments in Transition: Leadership in an era of transformation reveals that only 36% of payments executives have a clear long-term modernization roadmap, leaving many without a strategic vision for transformation. “In 2026, payments disruption won’t be incremental—it will be structural,” said Philip Bruno, Chief Strategy and Growth Officer at ACI Worldwide. “Real-time is now the baseline, digital assets are entering regulated ecosystems, and AI is transforming every layer of the value chain. Our research is a clear warning:
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom